T
Tatiana Boucard
Researcher at Environment Agency
Publications - 7
Citations - 862
Tatiana Boucard is an academic researcher from Environment Agency. The author has contributed to research in topics: Environmental exposure & Effects of global warming. The author has an hindex of 6, co-authored 7 publications receiving 801 citations.
Papers
More filters
Journal ArticleDOI
Chronic aquatic environmental risks from exposure to human pharmaceuticals.
TL;DR: There is little evidence of a general need to perform chronic aquatic invertebrate tests for all human pharmaceuticals, although further acute-to-chronic ratio data are required for the main therapeutic classes and modes of action of pharmaceuticals before this issue can be fully resolved.
Journal ArticleDOI
Impacts of climate change on indirect human exposure to pathogens and chemicals from agriculture.
Alistair B.A. Boxall,Anthony Hardy,Sabine Beulke,Tatiana Boucard,Laura Burgin,Pete Falloon,Philip M. Haygarth,Thomas H. Hutchinson,R. Sari Kovats,Giovanni Leonardi,Leonard S. Levy,Gordon Nichols,Simon A Parsons,Laura Potts,David A. Stone,Edward Topp,David B. Turley,Kerry Walsh,Elizabeth M. H. Wellington,Richard J. Williams +19 more
TL;DR: Overall, climate change is likely to increase human exposures to agricultural contaminants, and the magnitude of the increases will be highly dependent on the contaminant type.
Journal ArticleDOI
Environmental risk assessment for the serotonin re-uptake inhibitor fluoxetine: Case study using the European risk assessment framework.
Ken D. Oakes,Anja Coors,Beate I. Escher,Beate I. Escher,Kathrin Fenner,Jeanne Garric,Marion Gust,Thomas Knacker,Anette Küster,Carola Kussatz,Chris D. Metcalfe,Sara Monteiro,Thomas W. Moon,Jan A. Mennigen,Joanne L. Parrott,Alexandre R.R. Pery,Maria Ramil,Ines Roennefahrt,Jose Tarazona,Paloma Sánchez-Argüello,Thomas A. Ternes,Vance L. Trudeau,Tatiana Boucard,Glen Van Der Kraak,Mark R. Servos +24 more
TL;DR: The serotonin re-uptake inhibitor fluoxetine was selected for an environmental risk assessment, using the most recent European guideline (EMEA 2006), due to its environmental persistence, acute toxicity to nontarget organisms, and unique pharmacokinetics associated with a readily ionizable compound.
Journal ArticleDOI
Meeting Report : Risk Assessment of Tamiflu Use Under Pandemic Conditions
Andrew C. Singer,Bruce M. Howard,Andrew C. Johnson,Christopher J. Knowles,Simon A. Jackman,Cesare Accinelli,Anna Barra Caracciolo,Ian Bernard,Stephen Bird,Tatiana Boucard,Alistair B.A. Boxall,Jayne V. Brian,Elise Cartmell,Chris Chubb,John Churchley,Sandra Costigan,Mark Crane,M. J. Dempsey,Bob Dorrington,Brian Ellor,Jerker Fick,John Holmes,Thomas H. Hutchinson,Franz Karcher,Samuel L. Kelleher,Peter Marsden,Gerald Noone,Miles A. Nunn,John S. Oxford,Tony Rachwal,Noel A. Roberts,Michael S. Roberts,Maria Ludovica Saccà,Matthew B. Sanders,Jürg Oliver Straub,Adrian Terry,Dean Thomas,Stephen Toovey,Rodney Townsend,Nikolaos Voulvoulis,Chris Watts +40 more
TL;DR: The consensus was that oseltamivir ethylester-phosphate (OE-P) and oselTAMivir carboxylate (OC) were unlikely to pose an ecotoxicologic hazard to freshwater organisms.
Journal ArticleDOI
Recommendations on the environmental risk assessment of pharmaceuticals: Effect characterization
Heike Schmitt,Tatiana Boucard,Jeanne Garric,John Jensen,Joanne L. Parrott,Alexandre R.R. Pery,Jörg Römbke,Jürg Oliver Straub,Thomas H. Hutchinson,Paloma Sánchez-Argüello,Åke Wennmalm,Karen Duis +11 more
TL;DR: Suggestions for improving the effects testing of pharmaceuticals include inter alia chronic effects testing as a general approach, the use of invertebrate tests including sexual reproduction, the application of endpoints reflecting the mode of action of the drug or known side effects, and the simulation of more realistic exposure conditions in terrestrial laboratory tests.